Suspected Cancer in Primary Care: Guidelines for Investigation, Referral and Reducing Ethnic Disparities

Objectives

Provide evidence-based, clinically useful primary-care guidance for recognising possible cancer, undertaking appropriate initial investigation and making timely specialist referrals in New Zealand. The guideline supports practitioners, policy makers, patients and consumers while retaining professional judgement for individual cases.[1][2]It contributes to the Cancer Control Strategy by reducing cancer’s impact and incidence, reducing inequalities, improving access and outcomes, limiting late or missed diagnosis, reducing unwarranted variation, and using finite health-care resources appropriately.[2]

• Improve early recognition of concerning signs, symptoms, repeated presentations and relevant risk factors, from a person’s first primary-care presentation to their first specialist appointment.[2][3]
• Promote prompt and appropriate referral, including immediate referral within hours, urgent referral generally within two weeks, and referral through other appropriate pathways.[4][5]
• Support person- and whānau-centred decisions that account for comorbidity, personal preferences, family history, recurrence or metastatic disease, and, where appropriate, direct referral to palliative care.[6][7]
• Address ethnic disparities in diagnosis, access, stage at diagnosis, survival and mortality, with particular attention to Māori and Pacific peoples.[2][8][9]
• Promote culturally competent care, accessible communication, psychosocial support and tailored information for people and families or whānau during the period before diagnosis.[5][10][11]
• Cover suspected cancers across major adult cancer sites and children and young people, while excluding screening, prevention, health promotion, asymptomatic case-finding, recurrence, metastatic cancer, emergencies and secondary- or tertiary-care referrals from the core scope.[3]

The guideline additionally frames equity as a service and population-health priority. It calls for accurate ethnicity data, equitable and acceptable services, and appropriate resourcing to identify disparities, plan services and improve outcomes.[8]It identifies four connected barriers to cancer care, namely care costs, communication, structural access and cultural fit, requiring systematic and multifaceted responses rather than reliance on individual practitioner action alone.[12][13]

Implementation

Implement the guideline through a multilevel, evidence-informed approach that combines national direction, local adaptation, practitioner support, patient information, practice improvement and active action on inequities.[14][15]The Ministry of Health intended to commission a structured implementation plan, aligned with the New Zealand Cancer Control Strategy Action Plan 2005–2010 and Cancer Control Programme Sector Plan, involving national, regional and local networks.[14][16]

• Develop recommendations through the New Zealand Guidelines Group using systematic reviews, critical appraisal, evidence tables and multidisciplinary consensus, seeded by the 2005 National Institute for Health and Care Excellence suspected-cancer referral guideline and adapted to the New Zealand context.[1][3][17]
• Involve a multidisciplinary Guideline Development Team comprising general practice, radiology, oncology, nursing, palliative care, Māori and Pacific perspectives, consumers and other specialist expertise.[18][19]
• Grade recommendations by the quality and strength of supporting evidence, and use good practice points where evidence is unavailable but consensus or New Zealand consultation identifies important practice.[3][20][19]
• Disseminate key messages through general-practitioner summaries, primary-care training materials and academic, clinical, professional and public media, using multiple formats for practitioners, patients and support services.[15]
• Develop locally adapted protocols supported by reminders, educational outreach, interactive workshops, baseline-practice assessment and gap analysis against evidence-based care.[15][16]
• Engage the Ministry of Health, New Zealand Regional Cancer Networks, district health boards, primary health organisations, providers, professional bodies, Māori and Pacific communities, patients and whānau in delivery.[12][13][16]

Operationally, primary-care practitioners should assess symptoms in clinical context rather than applying recommendations in isolation; obtain a detailed history and examination; explain referral arrangements and expected timeframes; provide sufficient referral information and the preferred patient contact method; and follow up referrals where suspicion is high.[3][6][7]Investigations initiated in primary care should support, rather than delay, specialist referral.[21][22][23]

Equity-oriented implementation should collect high-quality ethnicity data, review practice and patient experience, provide communication and cultural-competency training with feedback, identify communication needs, and offer Māori- and Pacific-specific service components where required.[5][8]It should also reduce financial, geographical and organisational barriers through targeted funding, transport-subsidy awareness, flexible appointments, interpreters, community health workers, outreach in rural, marae and church settings, reminder systems and formal tracking of suspected-cancer referrals.[24]

Implementation should begin by measuring and documenting baseline clinical practice, identifying gaps from recommended care, prioritising gaps by population-health impact and disparity, identifying barriers and enablers, testing feasible solutions, and applying protocols or other corrective measures.[14][16]The guideline supports performance measurement, practice audit, feedback and patient-experience review, but does not provide a comprehensive national indicator set, reporting timetable, surveillance system, quantified targets or a formal accountability framework.[5][15]

The Ministry of Health funded development of the guideline, but no implementation budget, costed resource plan, funding allocation, quantified funding gap or economic assumptions are specified.[1][14][15]

Monitoring & Evaluation

The guideline combines evidence appraisal, implementation-performance measurement and equity-focused monitoring, but does not establish a single national evaluation framework, mandatory indicator set, reporting timetable or formal accountability body.[14][15][16]Its recommendations are graded by the strength of supporting evidence, while good practice points record development-team consensus or New Zealand consultation where evidence is lacking.[20][19]

• Measure and document baseline clinical practice against evidence-based recommendations, identify gaps, prioritise them by population-health impact and disparities, and develop protocols or corrective measures to improve alignment.[14][15][16]
• Monitor implementation performance across national, regional and local settings through a multilevel approach that includes locally adapted protocols, reminders, educational outreach, interactive workshops and baseline-practice assessment.[14][15]
• Review practice and patient experiences to improve culturally competent, patient-centred care, identify disparities, and assess whether Māori-specific cancer services or service components are needed.[15]
• Collect, record and analyse ethnicity data consistently, using Ministry of Health protocols, to monitor health trends, inequities, service effectiveness and progress in reducing disparities.[5][8][24]
• Monitor cancer incidence, mortality, stage at diagnosis, survival and screening uptake by ethnicity, cancer site, age and gender where data are available.[8][9][25][26]
• Use Tatau Kahukura: Māori Health Chart Book, published every three years, to document progress, while recognising that comparative screening and epidemiological data may be published with an approximate five-year lag.[8][9]
• Assess inequality using both absolute rate differences and relative rate ratios, because these measures may show different trends.[27]
• Track suspected-cancer referrals formally where feasible, follow up high-suspicion referrals, and inform patients about expected acknowledgement, specialist-assessment and investigation timeframes where available.[24][6][7]
• Use defined clinical process measures for selected conditions, including regular recording of smoking status, completion and reporting of urgent chest X-rays within one week, repeat imaging after lung consolidation, six-monthly alpha-fetoprotein testing for people with chronic hepatitis B or C, and mandatory follow-up after topical treatment of superficial basal cell carcinoma without histology.[28][29][30]
• Recognise surveillance limitations, including the absence of mandatory national registration for basal and squamous cell carcinomas under the Cancer Registry Act 1993.[30]
• Apply evidence-appraisal processes that assess study validity, effect magnitude, precision and applicability, supported by evidence tables and Considered Judgment Forms.[20]
• Use peer review and consultation as quality-assurance mechanisms, including circulation of the draft guideline to 337 individuals and organisations.[31]

Many cancer-specific sections provide epidemiological statistics, diagnostic evidence or referral expectations but do not specify routine outcome targets, implementation audits, reporting responsibilities or surveillance arrangements beyond the measures described above.[32][33][34][35]

Costing & Financing

Financing information is limited: the Ministry of Health funded guideline development, and the guideline identifies financial, time and resource barriers to equitable access and implementation, but provides no total budget, costed implementation plan, allocations, quantified funding gap or economic assumptions.[1][14][15]

• Fund guideline development through the Ministry of Health, although no monetary amount is specified.[1]
• Address costs of care as a barrier to cancer access, including consultation and prescription charges, home-visit costs, lost wages, travel expenses and childcare-related travel constraints.[36]
• Provide targeted funding for priority populations and improve awareness of transport subsidies to reduce financial barriers.[24]
• Resource culturally competent policies, practitioner training, feedback, community health workers, interpreters, tailored information, flexible appointments, outreach and mobile services, reminder systems and workforce development.[36][13][24]
• Allocate appropriate resources to achieve equity in cancer services, without specifying funding levels, sources or distribution mechanisms.[8]
• Recognise that geographical distance from major referral centres may create substantial time and financial implications for people requiring specialist assessment, particularly for suspected vulval cancer.[37]
• Account for implementation constraints related to inadequate skills, facilities, equipment, time and resources, alongside organisational, regional, practitioner and patient barriers.[14][15]
• Note that investigation access may vary with funding availability, access to medical technology and local protocols, but no investment requirements or economic appraisal are specified.[7]

No cost estimates, programme budgets, financing model, resource-mobilisation target, funding-gap analysis, cost-effectiveness assessment or economic assumptions are specified for cancer referral, investigation, psychosocial support or the wider implementation programme.[2][10][16]